2-piperidone has been researched along with Cardiac Hypertrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, XW; Kim, DJ; Kim, SY; Kim, W; Kim, YG; Lee, A; Lee, KH; Lee, SH; Lim, SJ; Moon, JY; Seo, JW; Woo, JS | 1 |
| Ban, Y; Fujii, T; Kawana, K; Konishi, R; Manson, JM; Nakatsuka, T | 1 |
2 other study(ies) available for 2-piperidone and Cardiac Hypertrophy
| Article | Year |
|---|---|
The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
Topics: Albuminuria; Animals; Apoptosis; Cardiomegaly; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Forkhead Box Protein O3; Forkhead Transcription Factors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Immunohistochemistry; Kidney; Male; Mice; NADPH Oxidases; Piperidones; Podocytes; Proto-Oncogene Proteins c-akt; Pyrimidines; Ventricular Dysfunction | 2016 |
Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Cardiomegaly; Dose-Response Relationship, Drug; Edema; Embryo, Mammalian; Embryonic and Fetal Development; Female; Fetal Diseases; Gestational Age; Heart Rate, Fetal; Hematoma; Male; Pericardium; Piperidones; Pregnancy; Rats; Rats, Sprague-Dawley; Spiro Compounds | 1994 |